Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1Phase 1 1

Status

Terminated 2Active not recruiting 2Completed 1

Sponsor Class

INDUSTRY 4OTHER 1

Study Type

Interventional 5

Sponsor

Cancer Type

Thoracic 5Gastrointestinal 1CNS 1

Conditions

Melanoma 17Colorectal Neoplasms 15Colonic Neoplasms 8Carcinoma, Non-Small-Cell Lung 5Brain Neoplasms 5Skin Neoplasms 4Rectal Neoplasms 4Neoplasms 4Lung Neoplasms 3Neoplasm Metastasis 2Gastrointestinal Neoplasms 2Digestive System Neoplasms 2Thyroid Neoplasms 1Solid Tumors 1Skin Diseases 1Rectal Diseases 1Pancreatic Neoplasms 1Neurofibromatosis 1 1Lymphatic Metastasis 1Leukemia, Hairy Cell 1Intestinal Neoplasms 1Intestinal Diseases 1Hereditary Sensory and Autonomic Neuropathies 1Gastrointestinal Diseases 1Disease Progression 1Digestive System Diseases 1Colonic Diseases 1Biliary Tract Neoplasms 1

Interventions

pembrolizumab 243Carboplatin 211Pemetrexed 177Cisplatin 131Paclitaxel 113Nivolumab 101Docetaxel 87osimertinib 85durvalumab 78Specimen Handling 56atezolizumab 55Gemcitabine 52Drug Therapy 52Magnetic Resonance Spectroscopy 50Radiosurgery 48Radiotherapy 47Ipilimumab 41130-nm albumin-bound paclitaxel 39cemiplimab 38Bevacizumab 34Cetuximab 30tislelizumab 29amivantamab 22Taxes 22Platinum Compounds 20Blood Specimen Collection 20Immunotherapy 18Immune Checkpoint Inhibitors 18Radiation 17Erlotinib Hydrochloride 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Carcinoma, Non-Small-Cell Lung × encorafenib × 1 year × Clear all
NCT04800822 2026-06-04

PF-07284892 in Participants With Advanced Solid Tumors

Pfizer

Phase 1 Terminated
53 enrolled
CNSGastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Neurofibromatosis 1, Hereditary Sensory and Autonomic Neuropathies, Colorectal Neoplasms

NCT05195632 2026-05-01

OCEANII

Pierre Fabre Medicament

Phase 2 Active not recruiting
63 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03915951 2026-03-24

An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer

Pfizer

Phase 2 Completed
98 enrolled 18 charts 1 FDA
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms

NCT04585815 2026-01-09

Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study)

Pfizer

Phase 1/2 Terminated
34 enrolled 44 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis

NCT04526782 2025-11-18

ENCO-BRAF

Intergroupe Francophone de Cancerologie Thoracique

Phase 2 Active not recruiting
119 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡